Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
FDA Accepts Application for Genentech’s Vabysmo for RVO
Genentech announced that the FDA has accepted the company’s supplemental biologics license application (sBLA) for Vabysmo (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). The sBLA is based on data from the phase 3 BALATON and…
Are Eye Pressure Fluctuation Normal or Cause for Concern?
Intraocular pressure (IOP) is a critical measurement in eye health, often associated with eye conditions like glaucoma. This pressure is the force exerted by the aqueous humor, the fluid inside the eye, on the ocular structures. Traditionally, eye pressure has…
Norlase Raises $11M in Funding for ECHO Pattern Laser
Norlase, a leading laser technology company, has recently secured its largest investment round to date, raising $11 million. This significant funding will empower Norlase to expedite the production ramp-up of its cutting-edge ECHO pattern laser, which recently received FDA clearance…
Stuart Therapeutics and Glaukos’ Exclusive License Deal
Stuart Therapeutics announced that it has signed an exclusive agreement with Glaukos Corporation. In this agreement, Glaukos gains exclusive global rights to develop and market Stuart’s proprietary drug candidate, ST-113, which focuses on neuroprotection in the context of glaucoma. ST-113,…
Alimera Wraps Synchronicity Study Enrollment for Yutiq in Uveitis
Alimera Sciences has reached its enrollment target for the Synchronicity study, marking a significant milestone in the prospective, open-label clinical investigation of Yutiq (fluocinolone acetonide intravitreal implant 0.18mg). The study focuses on assessing the safety and efficacy of Yutiq in…
Harrow Secures US and Canadian Rights to Vevye
Harrow has recently announced a significant development by entering the prescription dry eye disease treatment market. The company has successfully struck a deal to acquire the commercial rights for Vevye (cyclosporine ophthalmic solution 0.1%) in both the United States and…
2023 Recap: Top 15 Firsts in Ophthalmology
In a year marked by groundbreaking achievements, the field of ophthalmology witnessed a series of historic firsts, pushing the boundaries of innovation and patient care. Here are the noteworthy milestones: Pioneering the integration of technology into glaucoma management, the world’s…
Biocon Receives UK approval for YESAFILI®
Biocon Biologics announced that YESAFILI®, a biosimilar of Aflibercept, has been granted marketing authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. In September, YESAFILI® also received marketing authorization approval from the European Commission for the…
Aviceda’s IND Cleared by FDA for GA to AMD Treatment
Aviceda Therapeutics announced that the FDA has granted clearance for the IND for AVD-104. This clearance will allow the company to proceed with the initiation of Phase 2 clinical trials of its leading intravitreal ocular asset for the treatment of…
Patient Compliance: A Major Challenge for Ophthalmologists
According to the results of a recent LinkedIn survey conducted by our team, treating eye conditions can be a daunting task for medical professionals due to several challenges. Patient Compliance The survey asked attendees what their biggest challenge was when…